ReviewCancers2026
β-Glucans, Triterpenes and Nucleoside Analogs of Edible and Medicinal Mushrooms as Complementary Treatment in Diabetes and Cancer-A Review of Evidence from Clinical Trials.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a growing interest in preventive and complementary therapies to support health, increase the effectiveness of conventional medical treatments, and improve quality of life (QoL). This review summarizes the effects of β-glucans, triterpenes and nucleoside analogs of edible and/or medicinal mushrooms with results of clinical trials that investigated these effects in diabetes, breast-, prostate-, lung- and colorectal cancer patients. The results support that these components effectively alleviate symptoms and improve quality of life of these patients. Higher than 3 g of mushrooms, or equivalent extracts, per day are able to diminish metabolic parameters associated with diabetes, i.e., hyperglycemia, hyperlipidemia, and inflammation. The found survival benefit of mushrooms in breast cancer patients was subgroup- or marker-specific. Additionally, their immunomodulatory effects were more complex-different immunological parameters could be either activated or suppressed by different amounts. Data are limited for prostate cancer patients to date, but lentinan intake may increase the survival time of these patients. The survival of lung cancer patients is significantly improved with the use of beta-glucan as complementary therapy. However, its immunomodulatory role was not confirmed. The application of these mushroom components in patients with colorectal cancer may improve QoL. However, survival benefits are inconsistent across different clinical trials of these patients. In summary, although further randomized clinical trials are still required to evaluate optimal dosage and long-term mechanisms of actions in humans, edible and medicinal mushrooms may serve as valuable tools in preventive or in complementary therapies beside the conventional medical treatments of diabetes and cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.